Detection of skeletal muscle metastasis: torso FDG PET-CT versus contrast-enhanced chest or abdomen CT

So, Young; Yi, Jeong Geun; Song, Inmyung; Lee, Won Woo; Chung, Hyun Woo; Park, Jeong Hee; Moon, Sung Gyu

doi:10.1177/0284185114556927

Cited by 15 publications

(21 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest frequency of muscle metastases was in the hip, upper limb, and dorsal muscle, while subcutaneous metastases were mainly distributed in the chest, abdomen, and back. These findings are in line with those reported in the literature, and suggest that the staging of lung cancer should include a thorough examination of soft tissue [9,11,25,30,31].…”

Section: Survival Timesupporting

confidence: 91%

“…Generally, STM are asymptomatic and easy to miss during clinical evaluation [9,13]. Indeed, most of our patients (80%) did not present with symptoms related to their STM, and if 18 F-FDG PET/CT had not been performed, the lesions would have likely remained undetected.…”

Section: Survival Timementioning

confidence: 77%

“…At Lung cancer is the most common primary malignant tumor leading to STM [9][10][11][12][13]. More than half of lung cancer cases are diagnosed at an advanced stage [1,2].…”

Section: Survival Timementioning

confidence: 99%

“…Although skeletal muscle and subcutaneous soft tissue account for more than 50% of the human body weight, STM is relatively rare [6][7][8]. Lung cancer is the most common primary tumor of STM, with adenocarcinoma being the most common histological variant [9][10][11][12][13][14][15][16]. A recent study by Kanaji et al [17] showed that STM is associated with poor prognosis and worse response to treatment in lung cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

18F-FDG PET/CT is Valuable in Detecting Soft-tissue Metastasis of Lung Cancer

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Soft-tissue metastasis (STM) is a relatively rare, but not exceptional, manifestation of lung cancer. Since the lesions of STM are usually asymptomatic, they are easy to miss during clinical evaluation. The aim of the study was to explore the incidence and characteristics of STM in lung cancer using fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT), and evaluate its effect on tumor staging and treatment. Methods We analyzed 4543 patients with lung cancer who underwent 18 F-FDG PET/CT in our hospital between January 2013 and September 2018. 85 were diagnosed with STM and included in the study group. Imaging characteristics, clinical symptoms, and survival time (from confirmed STM to death) were recorded for all study subjects. Results A total of 219 lesions were identified by 18 F-FDG PET/CT: 215 were detected by PET (maximum standardized uptake value = 6.12); 139 were detected by CT. Muscle STM were primarily found in the hip, upper limb muscle; whereas subcutaneous STM were mainly distributed in the chest and abdomen, back. In 68 patients (80%), STM were found incidentally during routine 18 F-FDG PET/CT staging. The lesions were symptomatic in 17 cases (20%); in 10 patients (11.8%) STM was the first manifestation. Other site metastases were detected in 79 patients (92.9%). Isolated STM were found in 6 patients (7.1%), whose tumor staging and treatment were affected by PET/CT findings. At the end of the follow-up period, 69 patients were dead (median survival time= 5.0 months) and 5 were lost to follow-up. Conclusions STM may be a sign of advanced stage and poor prognosis in lung cancer. 18 F-FDG PET/CT is highly valuable in the detection of STM, and can impact tumor staging and management of lung malignancies.

show abstract

Section: Survival Timesupporting

confidence: 91%

Section: Survival Timementioning

confidence: 77%

“…At Lung cancer is the most common primary malignant tumor leading to STM [9][10][11][12][13]. More than half of lung cancer cases are diagnosed at an advanced stage [1,2].…”

Section: Survival Timementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

18F-FDG PET/CT is Valuable in Detecting Soft-tissue Metastasis of Lung Cancer

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…A total of 2 patients used a dedicated PET scanner (Allegro; Philips) (17), 3 patients used a 2 channel-CT integrated PET/CT (GEMINI; Philips) (18) and the remaining 21 patients used a 64-channel CT-integrated PET/CT scanner (DVCT; GE Healthcare Life Sciences) (19). FDG uptake was quantitated using the standardized uptake value (SUV).…”

Section: Methodsmentioning

confidence: 99%

F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis and prognosis prediction of vascular tumors

Lee

Kang

et al. 2017

Oncology Letters

Self Cite

View full text Add to dashboard Cite

The spectrum of vascular tumors ranges from hemangioma (HEM), to epithelioid hemangioendothelioma (EHE) and to angiosarcoma (AS). To the best of our knowledge, the usefulness of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) for vascular tumors has never been comprehensively studied. The present study investigated the usefulness of FDG-PET for pathologically diagnosed vascular tumors. The present study included 26 patients with vascular tumor (male:female, 17:9; age, 60.9±14.4 years; 7 HEM, 6 EHE and 13 AS) who underwent FDG-PET between January 2007 and May 2014 at the Seoul National University Bundang Hospital (Seongnam, Korea) and Konkuk University Medical Center, (Seoul, Korea). Representative FDG uptake was measured as the maximum standardized uptake value (SUVmax) over the lesion with the highest FDG uptake. Disease progression was clinically defined as the aggravation of known lesions or novel lesion development during follow-up on computed tomography, magnetic resonance imaging, or FDG-PET. FDG-PET revealed multi-organ involvement only in AS (6/13 [46.2%]), whereas HEM and EHE involved a single organ. Tumor SUVmax was significantly greater in AS (6.32±4.84) compared with EHE (3.10±2.68) and HEM (2.33±0.76) (P=0.0284). There was no difference in tumor SUVmax between HEM and EHE (P>0.05). Disease progression was primarily noticed in AS (9/13 [69.2%]). Only 1 patient with EHE (1/6=16.7%) and no patients with HEM (0/7=0%) experienced disease progression. Mortality was reported only in patients with AS (4/13 [30.8%]). Using the cutoff SUVmax of 3.0, the two-year progression-free survival rate of 14 patients with tumor SUVmax <3.0 (75.0%) was significantly higher compared with that of 12 patients with tumor SUVmax ≥3.0 (0%) (P=0.0053). In conclusion, FDG-PET is useful for the differential diagnosis and prognosis prediction of vascular tumors.

show abstract

Ultrasound and CT findings of subcutaneous metastases in trunk and pelvis: a comprehensive analysis

Kim,

Lee

et al. 2024

Skeletal Radiol

View full text Add to dashboard Cite

Detection of skeletal muscle metastasis: torso FDG PET-CT versus contrast-enhanced chest or abdomen CT

Abstract: The prevalence of SMM was as low as 0.41% in the current large cohort of cancer patients. Torso PET-CT was a more competent modality than contrast-enhanced CT in the detection of SMM.

Cited by 15 publications

References 13 publications

18F-FDG PET/CT is Valuable in Detecting Soft-tissue Metastasis of Lung Cancer

18F-FDG PET/CT is Valuable in Detecting Soft-tissue Metastasis of Lung Cancer

F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis and prognosis prediction of vascular tumors

Ultrasound and CT findings of subcutaneous metastases in trunk and pelvis: a comprehensive analysis

Contact Info

Product

Resources

About